Daily Ards Research Analysis
Analyzed 6 papers and selected 3 impactful papers.
Summary
Three distinct advances around acute respiratory distress emerged: a multimodal AI model accurately predicts ARDS in acute pancreatitis, a quasi-experimental ICU study links high-dose melatonin to lower 90-day mortality in COVID-19, and polyarginine chemistry enhances anti-inflammatory signaling and siRNA delivery in ARDS-relevant settings. Together they span prediction, repurposed therapeutics, and nanotechnology-enabled intervention.
Research Themes
- AI-driven ARDS risk prediction
- Therapeutic repurposing in critical illness
- Nanotechnology-enhanced anti-inflammatory therapy and nucleic acid delivery
Selected Articles
1. Arginine Polymerization Boosts Anti-Inflammatory Effects and DNA Nanostructure-Assisted siRNA Delivery in Acute Respiratory Distress Syndrome.
Polyarginine enhanced arginine’s anti-inflammatory activity in vitro, associated with upregulated IL-4, and enabled magnesium-free assembly of DNA nanostructures with improved cellular uptake. The team designed an arginine trimer-assembled DNA nanotube carrying p65 siRNA to validate polyarginine as an anti-inflammatory prodrug platform for ARDS.
Impact: Introduces a novel chemical-biology strategy that couples enhanced anti-inflammatory signaling with nucleic acid delivery, addressing a critical treatment gap in ARDS.
Clinical Implications: While preclinical, this platform suggests a path to targeted anti-inflammatory and gene-silencing therapies in ARDS, warranting in vivo efficacy, safety, and translational studies.
Key Findings
- Polyarginine markedly boosted the anti-inflammatory effects of arginine in vitro, with RNA-seq indicating upregulation of IL-4.
- Polyarginine enabled magnesium-free assembly of DNA nanostructures and enhanced cellular DNA uptake, improving delivery efficiency.
- An arginine trimer (3R)–assembled DNA nanotube carrying p65 siRNA was developed to validate polyarginine as an anti-inflammation prodrug platform.
Methodological Strengths
- Mechanistic interrogation with RNA transcription sequencing to define cytokine response (IL-4 upregulation).
- Demonstration of magnesium-free DNA nanostructure assembly with enhanced cellular uptake, supporting translational delivery potential.
Limitations
- Evidence is predominantly in vitro; in vivo efficacy and safety in ARDS models are not detailed in the abstract.
- Clinical translation, pharmacokinetics, and immunogenicity remain to be established.
Future Directions: Conduct in vivo ARDS model studies to quantify efficacy/safety, optimize polymer length and dosing, and evaluate translational feasibility and manufacturability.
Severe lung inflammation and acute respiratory distress syndrome (ARDS) represent one of the most life-threatening conditions in critical care units and no effective drugs are available clinically. Here, we show that the polymerization of arginine greatly boosts the anti-inflammatory effect of arginine in vitro. RNA transcription sequencing and analysis indicated that polyarginine upregulated the expression of the anti-inflammatory cytokine IL-4. Meanwhile, polyarginine can assemble DNA nanostructures in a magnesium-free manner and enhance the cellular uptake of DNA due to its cell-penetrating nature, thereby boosting DNA nanostructure-based drug delivery efficiency. To validate the potential of polyarginine as an anti-inflammation prodrug, an arginine trimer (3R) assembled DNA nanotube that carries p65 siRNA (NT
2. Multimodal prediction models integrating radiomics and three-dimensional deep learning for acute respiratory distress syndrome in acute pancreatitis patients.
In 759 acute pancreatitis patients across three hospitals, a multimodal model integrating clinical data, 3D CT radiomics, and 3D deep learning via XGBoost achieved AUCs of 0.872/0.876, outperforming CTSI, Ranson, BISAP, and unimodal models. Interpretability (SHAP/LIME), calibration, and decision-curve analyses supported robustness and clinical utility.
Impact: Provides a scalable, explainable AI tool for early ARDS risk prediction in acute pancreatitis, potentially improving triage and preventive care beyond traditional scores.
Clinical Implications: Can inform early risk stratification, ICU resource allocation, and proactive respiratory care in acute pancreatitis; prospective external validation and workflow integration are needed before deployment.
Key Findings
- Multimodal model AUCs: 0.872 (training) and 0.876 (test), exceeding traditional scores (CTSI, Ranson, BISAP).
- Outperformed single-modal radiomics (AUC 0.638/0.727) and deep learning alone (AUC 0.756/0.727).
- Incorporated interpretability (variable importance, SHAP, LIME), calibration plots, and decision-curve analysis to support clinical utility.
Methodological Strengths
- Multicenter cohort with sizable sample (n=759) and explicit comparison to established clinical scores.
- Model interpretability (SHAP/LIME) with calibration and decision-curve analyses to assess reliability and net clinical benefit.
Limitations
- Retrospective design with potential selection and imaging timing biases; external prospective validation not reported.
- Generalizability to different scanners/protocols and real-time clinical workflow integration remain untested.
Future Directions: Prospective multi-center external validation, impact analysis on clinical decision-making, and assessment of cost-effectiveness and workflow integration.
ObjectivesThis study aimed to develop a multimodal predictive model that integrates clinical data, radiomics, and three-dimensional deep learning to forecast acute respiratory distress syndrome in patients with acute pancreatitis.MethodsThis retrospective study analyzed data from 759 patients with acute pancreatitis treated at three hospitals. Radiomics features were extracted from three-dimensional computed tomography images, and a three-dimensional deep learning model was developed using convolutional networks. These components were combined with clinical data using the XGBoost algorithm to construct a multimodal model. The performance of the model was compared with that of single-modal models and traditional scoring systems (Modified Computed Tomography Severity Index, Ranson score, and Bedside Index for Severity in Acute Pancreatitis), using area under the curve as the primary metric. Model interpretability was enhanced using variable importance analysis, SHapley Additive exPlanations, local interpretable model-agnostic explanations, calibration plots, and decision curve analysis.ResultsThe multimodal model achieved area under the curve values of 0.872 (training set) and 0.876 (test set), outperforming traditional scores (Modified Computed Tomography Severity Index: 0.747 and 0.759; Ranson score: 0.575 and 0.568; and Bedside Index for Severity in Acute Pancreatitis: 0.748 and 0.757, respectively) and single-modal models (radiomics: 0.638 and 0.727 and deep learning: 0.756 and 0.727, respectively).ConclusionBy integrating clinical tabular data, radiomics, and deep learning features, the multimodal model can predict the risk of acute respiratory distress syndrome in patients with acute pancreatitis at an early stage.
3. Oral Melatonin in Critically Ill Patients With COVID-19: A Quasi-Experimental Pragmatic Trial.
In a quasi-experimental ICU study (n=335), high-dose oral melatonin (50–200 mg) added to standard care was associated with lower 90-day mortality (20.8% vs 36.1%; OR 0.46, 95% CI 0.28–0.76), reduced SOFA scores from day 4 onward, and fewer severe adverse events (RR 0.68; p=0.001) in critically ill COVID-19 patients.
Impact: Identifies a widely available, low-cost agent associated with improved survival and organ dysfunction in ICU COVID-19, warranting randomized trials.
Clinical Implications: High-dose melatonin could be considered for evaluation in RCTs as an adjunctive therapy in severe viral pneumonitis/ARDS settings; current data are insufficient for practice change due to nonrandomized design.
Key Findings
- 90-day mortality was lower with melatonin (20.8% vs 36.1%; OR 0.46, 95% CI 0.28–0.76).
- SOFA scores were reduced at days 4, 7, 14, and 30 in the melatonin group.
- Severe adverse events were fewer with melatonin (41.6% vs 60.2%; RR 0.68, 95% CI 0.54–0.87; p=0.001); high-dose oral melatonin appeared safe.
Methodological Strengths
- Pragmatic quasi-experimental design with alternating intervention/control periods and consecutive patient inclusion.
- Predefined outcomes including 90-day mortality, serial SOFA scores, and severe adverse events.
Limitations
- Nonrandomized time-period allocation introduces potential temporal and co-intervention confounding; lack of blinding.
- Single-system experience with potential changes in standard care across waves; generalizability and causality remain uncertain.
Future Directions: Conduct multicenter, randomized, blinded trials to confirm efficacy, define optimal dosing (50–200 mg range), and explore mechanisms (anti-inflammatory/antiviral).
Melatonin has demonstrated antioxidant, anti-inflammatory, and potential antiviral properties. Its therapeutic role in critically ill COVID-19 patients admitted to intensive care was underexplored at the start of the pandemic. We conducted a quasi-experimental, pragmatic study over 4 consecutive uninterrupted time periods alternating control groups receiving standard of care (SoC) with treatment groups receiving SoC plus high-dose oral bedtime melatonin (50-200 mg) (OBM). The primary endpoint was 90-day mortality; secondary outcomes included sequential organ failure assessment (SOFA) scores at 4, 7, 14, and 30 days and pre-defined severe adverse events (SAEs). A total of 335 of 339 consecutive patients with a predicted stay > 48 h were enrolled; 202 received OBM with SoC and 133 received SoC alone. OBM was dispensed during the second (n = 162) and fourth (n = 40) study periods after the first (n = 40) and third (n = 93) control group periods, respectively. Melatonin therapy was associated with significantly lower 90-day mortality (20.8% vs. 36.1%, OR 0.46, 95% CI 0.28-0.76). Subjects receiving melatonin had lower SOFA scores on Day 4 and subsequent study visits. SAEs occurred in 84 (41.6%) subjects on OBM and in 80 (60.2%) receiving SoC (risk ratio 0.68, 95% CI 0.54-0.87; p = 0.001). High-dose oral melatonin was safe and associated with improved clinical outcomes. Further evaluation of melatonin and its potential antiviral effects in future epidemics is warranted.